☆ 4.8 Article

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

NATURE MEDICINE (2021)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study

Wan Ni Chia et al.

Summary: The study investigated the dynamics of neutralising antibody response in patients who have recovered from COVID-19, finding great variations and suggesting that predicting immune longevity can only be accurately determined at the individual level. The findings emphasize the importance of public health and social measures in the ongoing pandemic outbreak response, and may have implications for the longevity of immunity after vaccination.

LANCET MICROBE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Functional SARS-CoV-2-Specific Immune Memory Persists after Mild COVID-19

Lauren B. Rodda et al.

Summary: The study found that individuals recovered from mild COVID-19 develop sustained SARS-CoV-2-specific immunological memory for at least 3 months, including immunoglobulin antibodies, neutralizing plasma, and memory B and T cells. These memory lymphocytes exhibit potent antiviral function, aiding in immune defense.

CELL (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Adaptive immunity to SARS-CoV-2 and COVID-19

Alessandro Sette et al.

Summary: The adaptive immune system, consisting of B cells, CD4(+) T cells, and CD8(+) T cells, plays varying roles in different viral infections and vaccines. Studies are showing that CD4(+) T cells, CD8(+) T cells, and neutralizing antibodies all play a part in controlling SARS-CoV-2 in COVID-19 cases, emphasizing the importance of understanding adaptive immunity in combating the disease.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Multidisciplinary Sciences

Correlates of protection against SARS-CoV-2 in rhesus macaques

Katherine McMahan et al.

Summary: Adoptive transfer of purified IgG from convalescent macaques protects naive macaques against SARS-CoV-2 infection, and cellular immune responses contribute to protection against rechallenge with SARS-CoV-2. The findings suggest that relatively low antibody titres are sufficient for protection against SARS-CoV-2 in macaques, while higher antibody titres are required for treatment of SARS-CoV-2 infection.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

Evolution of antibody immunity to SARS-CoV-2

Christian Gaebler et al.

Summary: After infection with SARS-CoV-2, antibody levels against the spike protein decrease significantly, but the number of memory B cells remain unchanged, indicating an evolving humoral response at 6.2 months after infection.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Looking beyond COVID-19 vaccine phase 3 trials

Jerome H. Kim et al.

Summary: Following the announcement of COVID-19 vaccine efficacy in clinical trials, a comprehensive strategy is needed for global vaccination, including manufacturing, support, supply coordination, equitable distribution, and logistics. Additionally, addressing scientific questions to improve vaccine efficacy is crucial for ending the pandemic effectively and efficiently.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Alicia T. Widge et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers

S. F. Lumley et al.

Summary: In a longitudinal study of seropositive and seronegative health care workers undergoing asymptomatic and symptomatic SARS-CoV-2 testing, the presence of anti-spike or anti-nucleocapsid IgG antibodies was associated with a substantially reduced risk of SARS-CoV-2 reinfection in the ensuing 6 months.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Daming Zhou et al.

Summary: The race to develop vaccines against SARS-CoV-2 variants, such as B.1.1.7, B.1.351, and P.1, is ongoing as these variants have mutations in the spike protein, potentially leading to immune escape. A structure-function analysis of B.1.351 revealed tighter ACE2 binding and widespread evasion from monoclonal antibody neutralization, particularly driven by the E484K mutation.

CELL (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Yanjun Zhang et al.

Summary: This study investigated the safety, tolerability, and immunogenicity of the COVID-19 vaccine candidate CoronaVac, and found that the 3 μg dose showed higher seroconversion rates in the phase 2 trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Raches Ella et al.

Summary: BBV152 vaccine, consisting of whole-virion inactivated SARS-CoV-2 with Algel and IMDG, showed high neutralizing antibody responses in phase 1 trial and better reactogenicity in phase 2 trial. The 6 mu g with Algel-IMDG formulation has been chosen for phase 3 efficacy trial.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Multidisciplinary Sciences

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Pengfei Wang et al.

Summary: The COVID-19 pandemic has had global repercussions, with promising vaccines and monoclonal antibody therapies. However, newly detected variants of SARS-CoV-2 present challenges to these treatment options.

NATURE (2021)

Add to Collection

Article Multidisciplinary Sciences

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Zijun Wang et al.

Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.

NATURE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies

Rita E. Chen et al.

Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.

NATURE MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine

Kai Wu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Letter Medicine, General & Internal

Neutralizing Activity of BNT162b2-Elicited Serum

Yang Liu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Multidisciplinary Sciences

Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19

Adam K. Wheatley et al.

Summary: The durability of infection-induced SARS-CoV-2 immunity has major implications for reinfection and vaccine development. Antibody, B cell, and T cell responses decline over the first 4 months post-infection, while S-specific IgG(+) memory B cells consistently accumulate. The study suggests that natural infection may only provide transient protection at a population level, highlighting the need for more immunogenic and durable vaccines.

NATURE COMMUNICATIONS (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Immunology

Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection

Deborah Cromer et al.

Summary: The duration of immunity to COVID-19 and the risk of reinfection remain unclear. Immunity is crucial for long-term control of the pandemic, but studies suggest a decline in antibody responses and an increase in documented cases of reinfection with SARS-CoV-2. Understanding memory responses and immune control dynamics is essential for designing vaccines and predicting the future trajectory of the pandemic.

NATURE REVIEWS IMMUNOLOGY (2021)

Add to Collection

Article Medicine, Research & Experimental

Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes

Edwards Pradenas et al.

Summary: The study found that individuals with mild or asymptomatic infections experienced an insignificant decrease in neutralizing activity, which persisted for 6 months after symptom onset or diagnosis. Hospitalized individuals exhibited higher neutralizing titers, which decreased rapidly at first but significantly slowed down after day 80, remaining higher than those with mild symptoms at 6 months. This slow decline in neutralizing activity contrasted with the constant decrease in anti-RBD, S2, or NP antibody titers over the follow-up period.

MED (2021)

Add to Collection

Article Immunology

Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection

Katharine H. D. Crawford et al.

Summary: Antibody levels, including neutralizing antibodies, decline after SARS-CoV-2 infection, with a 4-fold average decrease in titers from 1 to 4 months after symptom onset. This decline is accompanied by a decrease in total antibodies capable of binding the viral spike protein. Further studies are needed to determine the long-term durability of immunity to SARS-CoV-2, including examination of long-lived B cells and antibody titers over extended periods.

JOURNAL OF INFECTIOUS DISEASES (2021)

Add to Collection

Article Immunology

Influenza A Reinfection in Sequential Human Challenge: Implications for Protective Immunity and Universal Vaccine Development

Matthew J. Memoli et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Medicine, General & Internal

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti et al.

LANCET (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

Carolyn Rydyznski Moderbacher et al.

CELL (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19

Jennifer A. Juno et al.

NATURE MEDICINE (2020)

Add to Collection

Letter Medicine, General & Internal

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

F. Javier Ibarrondo et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

An mRNA Vaccine against SARS-CoV-2-Preliminary Report

L. A. Jackson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model

Thomas F. Rogers et al.

SCIENCE (2020)

Add to Collection

Article Medicine, General & Internal

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Edward E. Walsh et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Immunology

Measuring immunity to SARS-CoV-2 infection: comparing assays and animal models

David S. Khoury et al.

NATURE REVIEWS IMMUNOLOGY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Heterogeneity and longevity of antibody memory to viruses and vaccines

Alice Antia et al.

PLOS BIOLOGY (2018)

Add to Collection

Article Microbiology

Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model

Matthew J. Memoli et al.

MBIO (2016)

Add to Collection

Article Immunology

Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection

Arnold S. Monto et al.

JOURNAL OF INFECTIOUS DISEASES (2015)

Add to Collection

Article Ecology

Confidence intervals for ratios of proportions: implications for selection ratios

Ken Aho et al.

METHODS IN ECOLOGY AND EVOLUTION (2015)

Add to Collection

Article Statistics & Probability

Who Invented the Delta Method?

Jay M. Ver Hoef

AMERICAN STATISTICIAN (2012)

Add to Collection

Article Biochemical Research Methods

Comparison of neutralizing and hemagglutination-inhibiting antibody responses for evaluating the seasonal influenza vaccine

Li-Wei Cheng et al.

JOURNAL OF VIROLOGICAL METHODS (2012)

Add to Collection

Article Immunology

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

Steven Black et al.

PEDIATRIC INFECTIOUS DISEASE JOURNAL (2011)

Add to Collection

Article Health Care Sciences & Services

Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model

Laurent Coudeville et al.

BMC MEDICAL RESEARCH METHODOLOGY (2010)

Add to Collection

Article Statistics & Probability

Fast Implementation for Normal Mixed Effects Models With Censored Response

Florin Vaida et al.

JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS (2009)

Add to Collection

Article Medicine, General & Internal

Duration of humoral immunity to common viral and vaccine antigens

Ian J. Amanna et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Immunology

A framework for assessing immunological correlates of protection in vaccine trials

Li Qin et al.

JOURNAL OF INFECTIOUS DISEASES (2007)

Add to Collection

Article Mathematical & Computational Biology

A model for immunological correlates of protection

AJ Dunning

STATISTICS IN MEDICINE (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.